ERK1/2 promotes autophagic flux in chemoresistant gastric, breast, and ovarian cancer cells, but downregulates the same in basal or BRAF inhibitor resistant lung, breast, and PDAC cells10–12. Here, MAPK3 is linked to ovarian carcinoma.